Side Effects of rasagiline: A Synthesis of Findings from 20 Studies

  1. Home
  2. Side Effects of rasagiline
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of rasagiline: A Synthesis of Findings from 20 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of rasagiline: A Synthesis of Findings from 20 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Rasagiline is a monoamine oxidase B (MAO-B) inhibitor used to treat Parkinson's disease. Studies have shown that rasagiline can improve symptoms of Parkinson's disease and may slow disease progression. 6 Rasagiline is also effective as an adjunctive therapy to levodopa, helping to reduce levodopa-induced motor fluctuations and dyskinesias. 6 Rasagiline may be used for the treatment of early Parkinson's disease, and may also play a role in preventing dementia. 10

Reasons for Side Effects

Side effects of rasagiline are a result of its MAO-B inhibiting action. MAO-B is an enzyme that breaks down neurotransmitters in the brain. When rasagiline inhibits MAO-B, the amount of neurotransmitters increases, which can lead to side effects.

Common Side Effects

Gastrointestinal

Common side effects of rasagiline include gastrointestinal problems. Rasagiline can cause nausea, vomiting, constipation, and diarrhea. 3

Neuropsychiatric

Neuropsychiatric side effects include dizziness, headache, hallucinations, confusion, insomnia, depression, and anxiety. 3 Using rasagiline concurrently with antidepressants can increase the risk of serotonin syndrome. 4 Serotonin syndrome can cause symptoms like fever, muscle rigidity, and altered consciousness. 11

Other

Other side effects of rasagiline include hypertension, palpitations, rash, itching, and weight gain. 3

Side Effects Management

Gastrointestinal Side Effects

Gastrointestinal side effects can be managed with diet and medication. Dietary changes include eating easily digestible foods and drinking plenty of fluids. Medications include antiemetics and antidiarrheals.

Neuropsychiatric Side Effects

Neuropsychiatric side effects can be managed by reducing the dosage of rasagiline or discontinuing its use. Anti-anxiety and sleep medications may be prescribed as needed. If serotonin syndrome is suspected, seek immediate medical attention.

Other Side Effects

If you experience hypertension, palpitations, or other concerning side effects, consult with your doctor.

Comparison Across Studies

Commonalities

Multiple studies agree that rasagiline is effective in improving the symptoms of Parkinson's disease. 6 16 7 Studies also concur that the combination of rasagiline with other Parkinson's disease medications can enhance its effectiveness. 6 5

Differences

There are differences in the side effects reported in various studies. 3 For example, some studies report gastrointestinal side effects, while others highlight neuropsychiatric side effects. 3 Additionally, opinions differ regarding the neuroprotective effects of rasagiline. 10 Some studies suggest a neuroprotective effect, while others have not observed this effect.

Practical Considerations for Real-Life Application

Rasagiline holds promise as a treatment option for Parkinson's disease but must be considered alongside its potential side effects. 6 When taking rasagiline, adhere strictly to your doctor's instructions and report any side effects promptly. 6 Rasagiline can interact with other medications, so consult your doctor before taking it. 5

Current Research Limitations

Research on rasagiline is still ongoing. Further research is needed, especially on the long-term safety and effectiveness of rasagiline. 16 More conclusive evidence is required regarding the neuroprotective effects of rasagiline. 10

Future Research Directions

Large-scale clinical trials are needed to assess the long-term safety and efficacy of rasagiline. 16 Research using suitable animal models is required to validate the neuroprotective effects of rasagiline. 10 Furthermore, research aimed at understanding the mechanisms of action of rasagiline is crucial for developing more effective and safer drugs.

Conclusion

Rasagiline is a promising drug for the treatment of Parkinson's disease. However, it is important to consult your doctor before taking it, as it can cause side effects. 6 Research on rasagiline is still ongoing and further research is needed. 16

Literature analysis of 20 papers
Positive Content
19
Neutral Content
0
Negative Content
1
Article Type
3
1
0
6
19
1.

Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya.

Author: JaokoW G, MuchemiG, OguyaF O

Praziquantel
Schistosomiasis treatment
Abdominal pain
Headache
Nausea

Praziquantel was well-tolerated with mild and transient side effects.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

3.

Adverse effects produced by different drugs used in the treatment of Parkinson's disease: A mixed treatment comparison.

Author: LiBao-Dong, BiZhen-Yun, LiuJing-Feng, SiWei-Jun, ShiQian-Qian, XueLi-Peng, BaiJing

Improved treatment comparison

This mixed treatment comparison assessed the adverse effects of eleven drugs for Parkinson's disease (PD): ropinirole, rasagiline, rotigotine, entacapone, apomorphine, pramipexole, sumanirole, bromocriptine, piribedil, pergolide, and levodopa.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Language : English

4.

Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).

Author: PanissetMichel, ChenJack J, RhyeeSean H, ConnerJill, MathenaJulie,

No STS
STS risk

In this large retrospective cohort study, concurrent administration of rasagiline and antidepressants was not associated with serotonin toxicity syndrome.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Safety of rasagiline for the treatment of Parkinson's disease.

Author: Perez-LloretSantiago, RascolOlivier

Good tolerability
PD treatment
Safety profile

Rasagiline, a second generation monoamine oxidase B inhibitor, was discussed as a treatment for Parkinson's disease.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

7.

Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.

Author: ChenJack J, SwopeDavid M

Neuroprotection
Parkinson disease treatment
Cardiovascular side effects
Psychiatric side effects

Rasagiline is a novel, well-tolerated drug that irreversibly and selectively inhibits monoamine oxidase type B (MAO-B) for the treatment of Parkinson's disease (PD). It offers both symptomatic benefits and potential neuroprotection.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Safety and Effectiveness of Rasagiline in Chinese Patients with Parkinson's Disease: A Prospective, Multicenter, Non-interventional Post-marketing Study.

Author: SuWen, LiangZhanhua, MaoWei, ShaoMing, HuXingyue, WuYuncheng, WeiWenshi, LiuZhenguo, ZhangKezhong, TangBeisha, CaoShuai, SongZhuolun, ChenHaibo

Improves motor symptoms
Safe for PD
Nervous system disorders

Rasagiline is safe and well-tolerated in Chinese patients with Parkinson's disease (PD). In a prospective, non-interventional, multicenter, cohort study of 734 patients with PD, rasagiline monotherapy or adjunct therapy to levodopa was associated with a low incidence of adverse drug reactions (ADRs). The most common ADRs were nervous system disorders, gastrointestinal disorders, psychiatric disorders, vascular disorders, and general disorders. Improvements in motor function were observed in patients treated with rasagiline.

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.

Author: KongHaiyan, MengXianshe, HouRui, YangXiaoxiao, HanJihong, XieZhouling, DuanYajun, LiaoChenzhong

Parkinson's disease treatment

This study reports the development of novel hMAO-B inhibitors designed by linking rasagiline to hydrophobic fragments. Two compounds, K8 and K24, showed promising hMAO-B inhibitory activity, selectivity, and neuroprotective effects in preclinical studies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies.

Author: BindaClaudia, MilczekErika M, BoniventoDaniele, WangJin, MatteviAndrea, EdmondsonDale E

Neurodegenerative disease treatment
Neuroprotection

MAO inhibitors (MAOIs) are used for Parkinson's disease and depression. Safinamide, a selective MAO B inhibitor, shows neuroprotective effects. Rasagiline is used in combination with L-dopa and its metabolic products also have neuroprotective effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

12.

PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.

Author: NueblingGeorg, HenslerMira, PaulSabine, ZwergalAndreas, CrispinAlexander, LorenzlStefan

Rasagiline for PSP
Rasagiline side effects

Rasagiline, a MAO-B inhibitor, was well tolerated in patients with progressive supranuclear palsy, but did not show a significant effect on overall symptom progression.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

13.

Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease.

Author: ChitnisShilpa, JafferyManall, DeweyRichard B

Rotigotine efficacy

Rotigotine was an effective treatment for Parkinson's disease, with patients experiencing a decline in efficacy and side effects after switching to alternate therapies, except for the levodopa group.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

14.

Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan.

Author: HattoriNobutaka, TakedaAtsushi, TakedaShinichi, NishimuraAkira, KitagawaTadayuki, MochizukiHideki, NagaiMasahiro, TakahashiRyosuke

Improved motor function
Well tolerated
Nasopharyngitis

Oral rasagiline 1 mg/day was effective and well-tolerated in Japanese patients with early Parkinson's disease, with a significantly greater improvement in the MDS-UPDRS Part II+III total score compared to placebo, and a similar safety profile.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

15.

Advances in the pharmacologic management of early Parkinson disease.

Author: HauserRobert A, ZesiewiczTheresa A

Parkinson's treatment
Symptomatic benefit
Dyskinesias
Motor fluctuations

Levodopa, combined with a dopa decarboxylase inhibitor, is the most effective treatment for Parkinson's disease (PD), offering significant symptomatic benefits with minimal short-term side effects. However, the long-term use of levodopa is associated with the development of motor fluctuations and dyskinesias, highlighting the need for further research into long-term management strategies for PD.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.

Author: LöhleMatthias, ReichmannHeinz

Ameliorate motor symptoms

Early initiation of pharmacotherapy in Parkinson's disease (PD) is important, but there is ongoing controversy among neurologists about which substance to use for initial treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Potential of Natural Products of Herbal Origin as Monoamine Oxidase Inhibitors.

Author: OrhanIlkay Erdogan

Antidepressant
Anxiolytic
Neurodegenerative disease treatment

This review focuses on examples of in vitro and in vivo MAO-inhibiting natural compounds of plant origin isolated between 2000 - 2015.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.